帕丘利酒精对DSS诱导的性结肠炎的保护作用
Huifang Han1, Min Gao1, Fanghong Wang2
1Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 1, Yixueyuan Road, Yuzhong District, Chongqing, 400016, People's Republic of China.
Scientific reports
|July 20, 2024
概括
帕丘利酒精 (PA) 通过抑制特定的抗氧化剂通路,有效地预防性结肠炎模型中的炎症. 这种抗炎作用独立于肠道微生物组合的显著变化而发生.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 帕丘利酒精 (PA) 是中国传统草药 (THM) 的一个关键成分.
- PA因其调节肠道微生物群的潜力而得到认可.
- 性结肠炎 (UC) 涉及显著的肠道炎症和失生症.
研究的目的:
- 在UC模型中研究PA的抗炎作用.
- 确定PA对肠道微生物群组成和多样性的影响.
- 为了阐明PA的抗炎性能的作用机制 (MOA).
主要方法:
- 德克斯硫酸 (DSS) 诱导的UC小鼠模型.
- 评估UC症状严重程度和炎症标志物 (IL-1β,IL-6,TNF-α,CCL5) 的评估.
- 对肠道微生物群组成 (Firmicutes-Bacteroidetes比) 和多样性的分析.
- 对血氧酶-1 (HO-1) 和可诱导的氧化合成酶 (iNOS) 表达的评估.
主要成果:
- 在接受DSS治疗的小鼠中,PA治疗显著降低了炎症反应和促炎因子表达.
- 酸盐没有显著改变肠道微生物群的多样性,但增加了Firmicutes-Bacteroidetes比率.
- PA抑制了HO-1和iNOS的表达,这表明抗氧化途径的激活.
结论:
- 帕丘利酒精在DSS诱导的UC模型中显示出强大的抗炎作用.
- 通过直接抑制HO-1和iNOS信号通路,PA的治疗作用受到介导.
- 在这个模型中,PA的抗炎功效与其对肠道微生物群整体组成的影响无关.
相关概念视频
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
431
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
431
01:29Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
364
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
364
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
390
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
390
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156